Christina Kamelhair

Ogletree, Deakins, Nash, Smoak & Stewart, P.C.

+ Follow Contact

Latest Publications

Share:

DOJ Plans to Reclassify Marijuana From Schedule I to Lower-Risk Schedule III Drug

On April 30, 2024, following a months-long process, the U.S. Department of Justice (DOJ) circulated a proposal to reclassify marijuana from a Schedule I to a Schedule III controlled substance. ...more

5/2/2024 / Classification , Controlled Substances , Controlled Substances Act , DEA , Department of Health and Human Services (HHS) , Department of Justice (DOJ) , Internal Revenue Code (IRC) , IRS , Marijuana , Regulatory Reform , Schedule I Drugs

Stocking Naloxone in the Workplace: What Employers Need to Consider

It is well known that opioid overdoses have occurred at epidemic levels in the United States for years. According to the U.S. Centers for Disease Control and Prevention (CDC), opioid overdose deaths have increased from 21,089...more

10/25/2023 / Best Practices , Centers for Disease Control and Prevention (CDC) , Centers for Medicare & Medicaid Services (CMS) , Employee Training , FDA Approval , Food and Drug Administration (FDA) , NIOSH , Opioid , Over The Counter Drugs (OTC) , Recordkeeping Requirements

Indiana Approves Restrictions on Employer Vaccine Mandates: What Employers Need to Know

On March 3, 2022, the Indiana General Assembly passed House Bill 1001, which restricts employer COVID-19 vaccine mandates. This legislation - which was controversial out of the gate - was toned down significantly by the...more

3/4/2022 / Coronavirus/COVID-19 , Employer Liability Issues , Employer Mandates , Federal Contractors , Federal Employees , Infectious Diseases , Public Health Emergency , Vaccinations , Workplace Safety

3 Results

View per page

Page: of 1